Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Raloxifene for Paucisymptomatic COVID-19
NCT05172050Phase 3Completed
- Sponsor
- Dompé
- Start
- Jan 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial of raloxifene in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Dompé. Primary endpoints: Number of Participants With Undetectable SARS-CoV-2 at PCR at Day 7 and Number of Participants Not Requiring Oxygen Therapy and/or Mechanical Ventilation at Day 14. Started Jan 2021; status: completed.
02
Drugs
raloxifene
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05172050.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05172050.